Economic issues in coronary heart disease prevention.
The effectiveness of cholesterol lowering is well established, but cost-effectiveness is an increasing issue because of financial pressures on healthcare services. New statin studies have prospectively demonstrated that secondary prevention of coronary heart disease is almost always cost-effective, as is primary prevention in individuals at higher risk who have one or more other additional risk factors.
Reckless
J P
JP
School of Postgraduate Medicine, University of Bath, Royal United Hospital, UK.
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003327:Coronary Disease / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D017281:Cost of Illness; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008297:Male; D011314:Preventive Health Services / Q000191:economics*; D011322:Primary Prevention; D012307:Risk Factors
D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors